Abbott Laboratories has delivered a 24.6% share price gain over the past three years. The more pressing issue for you today is whether that track record lines up with the cash flows backing the stock. With new medical devices progressing through trials and regulatory pathways, the question now is how much of that future cash generation is already reflected in a US$109.93 share price.
- The 24.6% return over three years puts meaningful past gains on the table. This makes it more important to test whether Abbott’s current valuation is supported by the cash it can produce for shareholders.
- Positive trial results for devices like Amulet 360, SonicForce and the Cephea Mitral Valve System, together with growth initiatives in diabetes and neurostimulation, can influence expectations for future revenue streams, investment needs and ultimately the cash flows that underpin today’s market value.
- Prefer to judge Abbott Laboratories on earnings? See why Abbott Laboratories's 40.7x P/E tells a different valuation story.
The issue now is whether Abbott Laboratories’ current market price is justified by the cash flows implied by a Discounted Cash Flow (DCF) view over time.
If you want to test the same cash flow question across a wider set of medical and device-focused businesses, run the numbers through 29 resilient stocks with low risk scores.
Does Abbott Laboratories Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) approach here looks at the cash Abbott Laboratories can return to shareholders over time and discounts it back to today. On this view, the latest twelve month free cash flow sits at about $6.49b, with the model assuming those cash flows keep growing rather than shrinking over the coming decade.
Projected free cash flow by 2030 rises into the low $11b range, which is a sizeable step up from where Abbott is today and helps explain why the DCF estimate sits meaningfully above the current $109.93 share price. Positive clinical data for devices like Amulet 360 and SonicForce supports those long term cash flow expectations, because it feeds the pipeline of products that can turn into future dollars. The Discounted Cash Flow (DCF) projections put Abbott Laboratories' estimated intrinsic value meaningfully above the current share price, and that gap is what you can test for yourself with the detailed model inputs. Find out what Abbott Laboratories could be worth using our Discounted Cash Flow (DCF) estimate.
The Abbott Laboratories Narrative: What Would Justify Today's Price?
Narratives pick up where the Abbott Laboratories valuation puzzle leaves off. They spell out which assumptions on growth, margins and earnings would need to hold for Abbott Laboratories' stock to be worth meaningfully more or less than today's price. Each narrative focuses on the reasoning behind its fair value view, so you can line those assumptions up against actual results on Simply Wall St's Community page.
One of the top community narratives on Abbott Laboratories: 9% undervalued
"The main thing that has to go right is that Abbott Laboratories continues to convert its medical technology pipeline in areas like continuous glucose monitoring, electrophysiology and cancer diagnostics into sustained sales growth and margin expansion."
Discover why this Narrative puts Abbott Laboratories at 9% undervalued.
Abbott Laboratories’ valuation still leaves one powerful angle unexplored
Cash flow models and market pricing only tell part of the story. The people setting priorities at Abbott Laboratories, and the way their rewards are structured, can pull the whole picture in a very different direction. See who runs Abbott Laboratories and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com